<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/39263/presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311---common-questions-asked---timothy-heuer-ph.d.---twoxar-pharmaceuticals-twox.?channelName=Cancer-News" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

0:04:23

Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...

Name: Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...
Uploaded: 2020-08-28T03:14:05
Duration: 4 min 23 s
Description: Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 AACR2020 https://www.prnewswire.com/news-releases/twoxar-pharmaceuticals-presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311-301080554.html

Cancer-News

1 month

12 Views

Share Report Add to 0 0

Share Video (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/39263/presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311---common-questions-asked---timothy-heuer-ph.d.---twoxar-pharmaceuticals-twox.?channelName=Cancer-News" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Share Video (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://www.oncologytube.com/videoEmbed/39263/presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311---common-questions-asked---timothy-heuer-ph.d.---twoxar-pharmaceuticals-twox.?channelName=Cancer-News"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://www.oncologytube.com/videoEmbed/39263/presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311---common-questions-asked---timothy-heuer-ph.d.---twoxar-pharmaceuticals-twox.?channelName=Cancer-News" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Liver Cancer

Description:

Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311

AACR2020

https://www.prnewswire.com/news-releases/twoxar-pharmaceuticals-presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311-301080554.html